Hill-Rom (NYSE:HRC) had its price target boosted by analysts at Raymond James from $100.00 to $105.00 in a note issued to investors on Monday. The firm presently has an “outperform” rating on the medical technology company’s stock. Raymond James’ price target suggests a potential upside of 9.86% from the stock’s previous close.
HRC has been the subject of several other research reports. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a report on Tuesday, July 31st. Northcoast Research restated a “buy” rating and issued a $104.00 price objective on shares of Hill-Rom in a report on Tuesday, July 31st. KeyCorp upped their price objective on Hill-Rom from $97.00 to $115.00 and gave the company an “overweight” rating in a report on Tuesday, July 17th. Morgan Stanley upped their price objective on Hill-Rom from $95.00 to $100.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Finally, Zacks Investment Research lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $100.00.
Shares of Hill-Rom stock opened at $95.58 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.74 and a debt-to-equity ratio of 1.11. The firm has a market capitalization of $6.05 billion, a PE ratio of 20.12, a PEG ratio of 1.29 and a beta of 0.90. Hill-Rom has a fifty-two week low of $75.68 and a fifty-two week high of $98.96.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.12. The business had revenue of $759.20 million during the quarter, compared to analyst estimates of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.32 earnings per share. Equities analysts anticipate that Hill-Rom will post 5.09 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Vigilant Capital Management LLC purchased a new stake in shares of Hill-Rom during the second quarter valued at $109,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Hill-Rom during the second quarter valued at $173,000. CAPROCK Group Inc. purchased a new stake in shares of Hill-Rom during the third quarter valued at $211,000. Johanson Financial Advisors Inc. purchased a new stake in shares of Hill-Rom during the third quarter valued at $221,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Hill-Rom during the second quarter valued at $203,000. 80.65% of the stock is owned by institutional investors and hedge funds.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.